Pharmaceutical Breakfast of the Drug Security Forum

A country’s drug security is based on the success of its efforts in three key areas: ensuring citizens have access to high-quality, effective, and safe medicinal products; medicinal sovereignty; and scientific and technological leadership. Today, the main drivers of growth are fundamental and applied scientific research, as well as the advancement of personalized medicine, including cell-based technologies. Russia, meanwhile, remains critically dependent on imports of active pharmaceutical ingredients and continues to experience a shortage of domestic, full-cycle technological platforms. What mechanisms are being proposed for synchronizing scientific, manufacturing, and regulatory decisions in an effort to achieve the objectives of the country’s state policy in drug security? What state support measures are needed to incentivize the development of innovative molecules and expand domestic production of active ingredients? How can we strike a balance between accelerating the market launch of innovations and maintaining high standards of safety and efficacy? How are AI and digital solutions being integrated into the pharmaceutical industry, and does this require additional regulation? What impact will the development of a preferential regime have on the country’s medicinal sovereignty? Can improvements in procurement regulations, along with the introduction of outcome-based contracting models, enhance patients’ access to drugs and ensure budgetary savings?